Covered recipient · General Payments record
NILOFER AZAD
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2019–2024
$95,278.85
- Reported across 83 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $13,047.55 | 7 |
| Travel and Lodging | $865.18 | 4 |
| Food and Beverage | $222.83 | 4 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $3,573.86 | 6 |
| TAIHO ONCOLOGY, INC. | $3,246.04 | 3 |
| E.R. Squibb & Sons, L.L.C. | $2,880.00 | 1 |
| Acerta Pharma LLC | $2,740.00 | 2 |
| GlaxoSmithKline, LLC. | $1,600.00 | 1 |
| JAZZ PHARMACEUTICALS INC. | $50.67 | 1 |
| Tempus AI, Inc | $44.99 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,370.00 | 01/22/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104665883 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,370.00 | 05/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104487440 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,880.00 | 12/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101468701 | CMS |
| Eli Lilly and Company | $299.00 | 04/26/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1135237463 | CMS |
| Eli Lilly and Company | $44.10 | 04/26/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1135237467 | CMS |
| Eli Lilly and Company | $426.86 | 04/26/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1135288675 | CMS |
| Eli Lilly and Company | $95.22 | 04/26/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1135288679 | CMS |
| Eli Lilly and Company | $8.68 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135303995 | CMS |
| Eli Lilly and Company | $2,700.00 | 06/06/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1135251214 | CMS |
| GlaxoSmithKline, LLC. | $1,600.00 | 05/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1116509677 | CMS |
| JAZZ PHARMACEUTICALS INC. | $50.67 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150221476 | CMS |
| TAIHO ONCOLOGY, INC. | $118.49 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137935643 | CMS |
| TAIHO ONCOLOGY, INC. | $2,340.00 | 05/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1137937209 | CMS |
| TAIHO ONCOLOGY, INC. | $787.55 | 05/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1137944609 | CMS |
| Tempus AI, Inc | $44.99 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150160650 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.